Carbaglu: Acute hyperammonemia treatment

The medicine Carbaglu (Carglumic acid) was approved by the FDA in 2010 for treating patients who have acute hyperammonemia due to the deficiency of the hepatic enzyme N-acetyl glutamate synthase (NAGS) and chronic hyperammonemia due to the deficiency of the hepatic enzyme N-acetyl glutamate synthase (NAGS). Carbaglu treatment should be administered by a physician experienced in metabolic disorders. This medicine comes in the form of tablets of 200 mg for oral administration.
Carglumic acid price is economical, and one can find this medicine with several generic medicine suppliers. For more details, call us on 18008891064.
Tweet